NEWS

Results revealed from phase I clinical trial of the first drug to successfully inhibit the MYC gene, which drives many common cancers

peptomyc_20152022-11-04T12:28:09+00:0001 / 11 / 22|

Omomyc as the first MYC-targeted theraphy to succesfully complete a phase I clinical trial

peptomyc_20152022-11-04T12:28:48+00:0028 / 10 / 22|

TODAY in El Mundo: “Así avanza el fármaco español pionero en su estrategia contra el cáncer”

peptomyc_20152022-11-04T12:28:54+00:0026 / 10 / 22|

TODAY in La Vanguardia: “Èxit del primer assaig en pacients del fàrmac Omomyc contra el càncer”

peptomyc_20152022-11-04T12:29:04+00:0026 / 10 / 22|

EORTC-NCI-AACR (ENA) Symposium 2022 in Barcelona

peptomyc_20152022-11-04T12:29:12+00:0025 / 10 / 22|

MYC inhibition halts metastatic breast cancer progression by blocking tumor growth, invasion & seeding

peptomyc_20152022-11-04T12:29:18+00:0021 / 02 / 22|

Peptomyc receives 377.537€ from Spanish Mineco and European Union joint fund

peptomyc_20152022-11-04T12:29:23+00:0003 / 12 / 21|

PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial

peptomyc_20152022-11-04T12:29:50+00:0006 / 05 / 21|

Green light by the AEMPS to start clinical trials with OMO-103

peptomyc_20152022-11-04T12:30:01+00:0016 / 03 / 21|

Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board

peptomyc_20152022-11-04T12:30:55+00:0007 / 01 / 21|